2016
DOI: 10.3389/fphar.2016.00011
|View full text |Cite
|
Sign up to set email alerts
|

Matricryptins Network with Matricellular Receptors at the Surface of Endothelial and Tumor Cells

Abstract: The extracellular matrix (ECM) is a source of bioactive fragments called matricryptins or matrikines resulting from the proteolytic cleavage of extracellular proteins (e.g., collagens, elastin, and laminins) and proteoglycans (e.g., perlecan). Matrix metalloproteinases (MMPs), cathepsins, and bone-morphogenetic protein-1 release fragments, which regulate physiopathological processes including tumor growth, metastasis, and angiogenesis, a pre-requisite for tumor growth. A number of matricryptins, and/or synthet… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

1
44
0

Year Published

2017
2017
2024
2024

Publication Types

Select...
7
1
1

Relationship

0
9

Authors

Journals

citations
Cited by 59 publications
(45 citation statements)
references
References 175 publications
(174 reference statements)
1
44
0
Order By: Relevance
“…6) In a broad sense, the fragments of ECM-associated enzymes (MMPs, a disintegrin and metalloproteinases and lysyl oxidase) and ECM-affiliated proteins (e.g., mucins, galectins and semaphorins) are also considered as matricryptins. [7][8][9] Because most matricryptins have been clarified to be an endogenous anti-angiogenic and/or anti-tumor factor, they are expected to be novel anti-tumor drugs and are thus being widely investigated. 10) Matricryptins also regulate fibrosis, wound-healing, inflammation and vasocontractility, and are considered to be associated with various diseases, such as cancer, arthritis, pulmonary and kidney disease.…”
Section: Introductionmentioning
confidence: 99%
“…6) In a broad sense, the fragments of ECM-associated enzymes (MMPs, a disintegrin and metalloproteinases and lysyl oxidase) and ECM-affiliated proteins (e.g., mucins, galectins and semaphorins) are also considered as matricryptins. [7][8][9] Because most matricryptins have been clarified to be an endogenous anti-angiogenic and/or anti-tumor factor, they are expected to be novel anti-tumor drugs and are thus being widely investigated. 10) Matricryptins also regulate fibrosis, wound-healing, inflammation and vasocontractility, and are considered to be associated with various diseases, such as cancer, arthritis, pulmonary and kidney disease.…”
Section: Introductionmentioning
confidence: 99%
“…Several of them can inhibit angiogenesis by modulating endothelial cell proliferation (e.g., anastellin derived from fibronectin, endostatin from collagen type XVIII), apoptosis (e.g., arresten from collagen IV) or autophagy (endostatin and endoreppelin from perlecan). Others also can affect either cancer cell migration (arresten) or proliferation (endostatin) .…”
Section: Ecm As a Gatekeeper In Cancer Initiation And Progressionmentioning
confidence: 99%
“…In addition to its structural role, the proteolytic degradation of the vBM generates various bioactive fragments called matricryptins to regulate endothelial cell proliferation, migration, and survival as well as to help limit excessive angiogenesis during wound healing, inflammation, and disease processes. Several extracellular matrix (ECM) components can contribute to the generation of these fragments, notably, collagens IV (arresten; canstatin; tumstatin) and XVIII (endostatin) and heparan sulfates (endorepellin) [157]. …”
Section: Anti-angiogenesismentioning
confidence: 99%
“…In humans, this activity is catalyzed by a tightly regulated family of 23 zinc-dependent endopeptidases known as matrix metalloproteinases (MMPs) which are secreted in response to growth factor signaling and are essential for initiating the process of angiogenesis (reviewed in [6]). MMP pro-angiogenic functions are controlled by the generation of anti-angiogenic matricryptins (described above) as well as endogenous inhibitors of MMP activity in the form of TIMPs [157, 181]. TIMPs are a family of four proteins (TIMP 1–4; 20–29 kDa) that bind to active sites of MMPs and inhibit their proteolytic activities.…”
Section: Anti-angiogenesismentioning
confidence: 99%